IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor Microenvironment.

Jianmin Zhu,Jianyu Yu,Aiyan Hu,Jin-Qing Liu,Xueliang Pan,Gang Xin,William E. Carson,Zihai Li,Yiping Yang,Xue-Feng Bai

DOI: https://doi.org/10.4049/jimmunol.2300176

2023-01-01

The Journal of Immunology

Abstract:IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple lineages of immune cells and has a potential to be used as a therapeutic for cancer. We have recently demonstrated that administration of IL-27 producing adeno-associated virus (AAV-IL-27) exhibits potent inhibition of tumor growth in mouse models. In this study, we demonstrate that AAV-IL-27 treatment leads to significant expansion of CD11b(+)Gr1(+) myeloid cells. AAV-IL-27-induced expansion of CD11b(+)Gr1(+) cells is IL-27R-dependent and requires Stat3 signaling, but it is inhibited by Stat1 signaling. AAV-IL-27 treatment does not increase the self-renewal capacity of CD11b(+)Gr1(+) cells but induces significant expansion of Lin(-)Sca1(+)c-Kit(+) (LSK) and granulocyte-monocyte progenitor cells. Despite exhibiting significant suppression of T cells in vitro, IL-27-induced CD11b(+)Gr1+ cells lost the tumor-promoting activity in vivo and overall play an antitumor role. In tumors from AAV-IL-27-treated mice, CD11b(+)Gr1(+) cells are largely F4/80(+) and express high levels of MHC class I/II and M1 macrophage markers. Thus, IL-27 gene therapy induces Stat3-mediated expansion of CD11b(+)Gr1(+) myeloid cells and promotes accumulation of M1 macrophages in the tumor microenvironment.